Beyondspring (BYSI) Gets a Buy Rating from William Blair


In a report issued on June 7, Andy Hsieh from William Blair maintained a Buy rating on Beyondspring (BYSI). The company’s shares closed last Thursday at $11.37.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 12.0% and a 54.7% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Vaccitech Plc Sponsored ADR, Actinium Pharmaceuticals, and Nektar Therapeutics.

Beyondspring has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.50 and a one-year low of $9.24. Currently, Beyondspring has an average volume of 186.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts